Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for AS Latvijas Juras medicinas centrs's Return-on-Tangible-Equity or its related term are showing as below:
ORSE:LJM1R'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -9.59 Med: 3.43 Max: 14.84
Current: 3.86
During the past 13 years, AS Latvijas Juras medicinas centrs's highest Return-on-Tangible-Equity was 14.84%. The lowest was -9.59%. And the median was 3.43%.
ORSE:LJM1R's Return-on-Tangible-Equity is not ranked
in the Healthcare Providers & Services industry.
Industry Median: 10.085
vs ORSE:LJM1R: 3.86
AS Latvijas Juras medicinas centrs (ORSE:LJM1R) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
AS Latvijas Juras medicinas centrs Return-on-Tangible-Equity Related Terms
AS Latvijas Juras medicinas centrs Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AS Latvijas Juras medicinas centrs Return-on-Tangible-Equity Chart
ORSE:LJM1R vs HCA, THC, ENSG: Return-on-Tangible-Equity Comparison
For the Medical Care Facilities subindustry, AS Latvijas Juras medicinas centrs's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AS Latvijas Juras medicinas centrs Return-on-Tangible-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, AS Latvijas Juras medicinas centrs's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where AS Latvijas Juras medicinas centrs's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 0.63% mean?
AS Latvijas Juras medicinas centrs (ORSE:LJM1R) has a Return-on-Tangible-Equity of 0.63% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on AS Latvijas Juras medicinas centrs and its competitors. This is 82% below median its historical median of 3.43.
Is AS Latvijas Juras medicinas centrs' Return-on-Tangible-Equity too high?
AS Latvijas Juras medicinas centrs' current Return-on-Tangible-Equity of 0.63% is 82% below median its 10-year median of 3.43. The Healthcare Providers & Services industry median Return-on-Tangible-Equity is 10.09. AS Latvijas Juras medicinas centrs' value of 0.63% is 93.8% below this industry median. Overall, AS Latvijas Juras medicinas centrs has a GF Score™ of 59/100, reflecting its overall financial health beyond just this single metric.
How does AS Latvijas Juras medicinas centrs' Return-on-Tangible-Equity compare to HCA and THC?
AS Latvijas Juras medicinas centrs' Return-on-Tangible-Equity of 0.63% can be compared against companies in the Healthcare Providers & Services industry. The industry median Return-on-Tangible-Equity is 10.09. AS Latvijas Juras medicinas centrs' value of 0.63% is 93.8% below this benchmark. While the company's 10-year median is 3.43 vs. the industry median of 10.09, AS Latvijas Juras medicinas centrs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 10.09, based on 580 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AS Latvijas Juras medicinas centrs's current Return-on-Tangible-Equity of 0.63% is 93.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on AS Latvijas Juras medicinas centrs and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 10.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AS Latvijas Juras medicinas centrs's current Return-on-Tangible-Equity is 0.63%, which is 82% below median its own 10-year median of 3.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AS Latvijas Juras medicinas centrs stock overvalued right now?
AS Latvijas Juras medicinas centrs (ORSE:LJM1R) has a current Return-on-Tangible-Equity of 0.63%. The stock's GF Value™ is €7.78, compared to a current price of €7.80 — trading 0.3% above its estimated fair value. The current Return-on-Tangible-Equity is 0.63%, which is 82% below median its 10-year median of 3.43 and 93.8% below the Healthcare Providers & Services industry median of 10.09. AS Latvijas Juras medicinas centrs' overall GF Score™ is 59/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For AS Latvijas Juras medicinas centrs (ORSE:LJM1R), the current Return-on-Tangible-Equity is 0.63% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AS Latvijas Juras medicinas centrs (ORSE:LJM1R) Overvalued in 2026?
Based on GuruFocus' analysis, AS Latvijas Juras medicinas centrs stock appears to be overvalued.
The current stock price of €7.80 is trading 0.3% above its estimated GF Value™ of €7.78.
Key valuation signals for ORSE:LJM1R:
Return-on-Tangible-Equity: 0.63% (82% below median its 10-year median of 3.43)
GF Value™: €7.78 vs. price of €7.80 (0.3% above fair value)
Industry Position: 93.8% below the Healthcare Providers & Services median
No single metric tells the full story. See the ORSE:LJM1R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AS Latvijas Juras medicinas centrs Business Description
AS Latvijas Juras medicinas centrs is a private certified medical institution in Latvia providing outpatient and inpatient healthcare services through qualified staff and modern equipment. Its core activities include hospital services, orthopaedic retail, medical and dental practice, human health and residential care, social work activities, and physical well-being services. It operates the Women's Health Clinic, offering gynecological consultations, pregnancy care, diagnostics, postpartum services, gynecological care for girls, and surgery. The centre also provides vaccination, rehabilitation, a Multiple Sclerosis Center, medical commission, home visits, laboratory services, physical medicine and massage, therapeutic procedures, medical treatment, and anesthesia and intensive care.
59GF Score
Get the complete analysis for ORSE:LJM1R
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ORSE:LJM1R has been successfully added to your 
